Myeloproliferative Neoplasms (MPN)

CROSS-DISEASE TRIAL:

- **IRB#10262**
  - Oral Ruxolitinib for CNL or atypical CML.

**MPN**

- **Myelofibrosis**
  - **IRB# 19142**
    - Open-Label, Ph 2a/2b of KRT-232 in Subjects with Primary Myelofibrosis (MF), Post-Polycythemia Vera MF, or Post-Essential Thrombocytethemia MF who have failed prior treatment with a JAK Inhibitor.
  - **IRB# 16363**
    - Phase 2 INCBO50465 plus Ruxolitinib.
  - **IRB# 20542**
    - Study coming soon.

- **Systemic Mastocytosis**
  - **IRB# 17155**
    - Phase 1 of DCC-2618 in Advanced Malignancies.

- **Polycythemia vera**
  - **IRB# 19144**
    - 2-Part, Randomized, Open-label, Ph 2a/2b of KRT-232 Compared to Ruxolitinib in Phlebotomy-Dependent Polycythemia Vera.
  - **IRB# 15977**
    - Non Treatment National MDS Study (ECOG/ACRIN).

**CNL/atypical CML**

**http://www.ohsu.edu/research/rda/so/knight.php**

**Key**

- Open for Enrollment
- In Development
- Enrollment on Hold